Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front and fairly positive results reported by pharma giant Johnson & Johnson JNJ.
Equillium Inc EQ was among the biggest gainers of the week after a drug that it licensed from Biocon was granted emergency use authorization in India for treating cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.
Moderna Inc MRNA advanced in all five sessions of the week, with detailed interim Phase 1 data publication, positive sell-side commentary and news of inclusion in the Nasdaq 100 Index serving as catalysts.
The following are key catalysts in the unfolding week.
Galactosemia Foundation 2020 Virtual Conference, July 17-19
The FDA is set to rule on Jazz Pharmaceuticals PLC's JAZZ NDA for JZP-258, which is being evaluated as a treatment option for cataplexy —excessive daytime sleepiness — in patients 7 and older with narcolepsy.
- Biogen Inc BIIB (Wednesday, before the market open)
- Quest Diagnostics Inc DGX (Thursday, before the market open)
- West Pharmaceutical Services Inc. WST (Thursday, before the market open)
- Edwards Lifesciences Corp EW (Thursday, after the close)
- LeMaitre Vascular Inc LMAT (Thursday, after the close)
ACell, a regenerative medicines company that develops products designed to facilitate the body's ability to repair and remodel tissue, is planning a 5-million-share IPO at an estimated price range of $14-$16. The company has applied for listing its shares on the Nasdaq under the ticker symbol "ACLL."
IPO Quiet Period Expirations
- Polypid Ltd PYPD
- Akouos Inc AKUS
- Fusion Pharmaceuticals Inc FUSN
- ADiTx Therapeutics Inc ADTX
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.